Alector reports fourth quarter and full year 2022 financial results and provides corporate update

On track to complete enrollment in the invoke-2 phase 2 clinical trial of al002 in patients with early alzheimer's disease in q3 2023, with data readout expected by q4 2024

ALEC Ratings Summary

ALEC Quant Ranking